Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Heat Biologics Inc (HTBX)

Heat Biologics Inc (HTBX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,047
  • Shares Outstanding, K 25,650
  • Annual Sales, $ 2,110 K
  • Annual Income, $ -35,070 K
  • 60-Month Beta 0.45
  • Price/Sales 28.77
  • Price/Cash Flow N/A
  • Price/Book 0.54
Trade HTBX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.41
  • Most Recent Earnings -0.54 on 03/14/22
  • Next Earnings Date 05/04/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 84.35%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate -0.46
  • Number of Estimates 1
  • High Estimate -0.46
  • Low Estimate -0.46
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -48.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.22 +7.20%
on 04/27/22
3.38 -29.59%
on 04/18/22
-0.71 (-22.98%)
since 04/01/22
3-Month
2.07 +14.98%
on 03/14/22
3.38 -29.59%
on 04/18/22
-0.40 (-14.39%)
since 02/02/22
52-Week
2.07 +14.98%
on 03/14/22
10.85 -78.06%
on 06/10/21
-4.49 (-65.36%)
since 04/30/21

Most Recent Stories

More News
NightHawk Biosciences Provides First Quarter 2022 Business Update

DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on...

HTBX : 2.38 (+0.42%)
NHWK : 2.30 (-2.54%)
Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today

DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated...

HTBX : 2.38 (+0.42%)
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics

Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE...

HTBX : 2.38 (+0.42%)
Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas, available for replay at Nighthawkbio.com...

HTBX : 2.38 (+0.42%)
Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility

500,000+ square foot facility to support commercial-scale biomanufacturing Livestreaming ceremony with Governor Laura Kelly Live from Manhattan, Kansas...

HTBX : 2.38 (+0.42%)
Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments

DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused...

HTBX : 2.38 (+0.42%)
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process

New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and...

HTBX : 2.38 (+0.42%)
Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company

Burel to support anthrax and RapidVax™ biodefense initiatives as a platform for rapid response to known and unknown biological threats...

HTBX : 2.38 (+0.42%)
Heat Biologics Announces Planned Transfer to the NYSE American

DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on...

HTBX : 2.38 (+0.42%)
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services

Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an...

HTBX : 2.38 (+0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company's products under development include HS-110 for the treatment of non-small cell...

See More

Key Turning Points

3rd Resistance Point 2.61
2nd Resistance Point 2.55
1st Resistance Point 2.46
Last Price 2.38
1st Support Level 2.31
2nd Support Level 2.25
3rd Support Level 2.16

See More

52-Week High 10.85
Fibonacci 61.8% 7.50
Fibonacci 50% 6.46
Fibonacci 38.2% 5.42
Last Price 2.38
52-Week Low 2.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar